34 studies found for:    " December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.
Condition: HIV Integrase, HIV Protease.
Interventions: Drug: Raltegravir;   Drug: Darunavir
22 Recruiting Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Condition: HIV
Intervention: Drug: Etoricoxib
23 Active, not recruiting Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.
Conditions: HIV;   Cardiovascular Disease
Interventions: Drug: raltegravir plus truvada;   Drug: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
24 Not yet recruiting Project Wellness: Increasing HIV Testing Among West African Immigrants
Conditions: Diabetes;   Hypertension;   HIV
Interventions: Behavioral: HIV testing;   Behavioral: General Health Screen
25 Completed Study of SystemCHANGE-HIV
Condition: HIV
Intervention: Behavioral: SystemCHANGE-HIV
26 Terminated Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis
27 Active, not recruiting Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Condition: Tuberculosis
Interventions: Biological: GSK's investigational vaccine 692342;   Biological: Physiological saline
28 Completed
Has Results
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Condition: HIV
Interventions: Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
29 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV
Interventions: Drug: TMC278;   Drug: Efavirenz
30 Not yet recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
31 Active, not recruiting Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings
Condition: HIV
Intervention:
32 Completed Familias Unidas: Preventing Drug Abuse and HIV in Hispanic First Offenders
Conditions: Substance Use;   Unsafe Sexual Behavior
Intervention: Behavioral: Familias Unidas
33 Enrolling by invitation Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Condition: Kaposi's Sarcoma
Intervention: Drug: Maraviroc
34 Unknown  Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence
Condition: Use of Research Evidence
Intervention: Other: SHARE (Synthesized HIV/AIDS Research Evidence)

Show previous page of results Previous Page (1-20) Studies Shown (21-34) Next Page
Indicates status has not been verified in more than two years